Keyphrases
Adverse Events
12%
Annualized Relapse Rate
29%
Cladribine
11%
Clinical Diagnosis
11%
Clinical Disease
11%
Clinical Disease Activity
11%
Confidence Interval
14%
COVID-19 Vaccination
11%
Danish Population
12%
Data Networks
22%
Denmark
31%
Diagnostic Uncertainty
6%
Disability
6%
Disease Activity
24%
Disease Course
6%
Disease Risk
9%
Disease-modifying Therapy
27%
Europe
11%
European Registries
11%
Expanded Disability Status Scale
28%
Fingolimod
11%
Health Systems
11%
International Registry
11%
Life Perspectives
11%
MS Diagnosis
11%
MS Patients
8%
Multiple Sclerosis
100%
Multiple Sclerosis MS
9%
Multiple Sclerosis Treatment
31%
Natalizumab
9%
Natalizumab Treatment
11%
National Cohort Study
30%
Newly Diagnosed
11%
Ocrelizumab
11%
Population-based Cohort Study
11%
Prognostic Factors
11%
Progressive MS
27%
Progressive multiple Sclerosis
18%
Real-world Experience
11%
Registry Research
11%
Relapse Pattern
11%
Relapse Risk
9%
Relapsing-remitting MS
22%
Relapsing-remitting multiple Sclerosis
27%
Single-center Study
11%
Socioeconomic Status
11%
Sweden
9%
Teriflunomide
11%
Treatment Predictors
11%
Treatment Switching
11%
